Pinealon preserved dendritic spines in Alzheimer's-model mice

What is Pinealon?

Pinealon is a synthetic tripeptide, glutamate-aspartate-arginine (Glu-Asp-Arg, abbreviated EDR), developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology ^[1]⁠^[2]⁠^[3].

The institute proposes a family of short peptides, usually two or three amino acids, as tissue-specific "bioregulators," one peptide per organ system. EDR is their central nervous system candidate.

How is Pinealon supposed to work?

Pinealon is proposed to act on gene transcription, and the lab that developed it advances three components. The peptide enters cells and interacts with chromatin or RNA to influence transcription, it suppresses reactive oxygen species, and it modulates proteins involved in programmed cell death, including caspase-3 and p53 ^[2]⁠^[3].

Molecular docking work from the same lab identified predicted EDR binding sites in the promoter regions of genes relevant to Alzheimer's-model biology, including APOE, CASP3, SOD2, NES, GAP43, PPARA, and PPARG ^[1].

That is a coherent hypothesis, not established pharmacology. Direct peptide-DNA binding as a mode of action for a three-residue peptide is mechanistically plausible, and it remains a specific, still-debated claim advanced almost entirely by the group that developed the compound. Docking predictions show where a molecule could bind based on structural modeling. They do not demonstrate that binding drives a functional change in gene expression inside a living human brain.

What do cell studies of Pinealon show?

In cell studies, Pinealon reduced reactive oxygen species in a dose-dependent way and lowered rates of necrotic cell death ^[3]. Those experiments used rat cerebellar granule cells, neutrophils, and PC12 cells. At higher concentrations the authors reported evidence consistent with direct genome interaction, which they inferred rather than directly visualized ^[3].

A 2024 study used induced neurons, cells reprogrammed directly from skin fibroblasts of elderly human donors, rather than an animal model. EDR exposure increased dendritic branching, producing more primary processes and greater total dendrite length. It also showed a trend toward less oxidative DNA damage on the 8-OHdG marker, and that finding sat at p=0.0566, just past the conventional threshold for statistical significance ^[5].

That induced-neuron work is the most human-relevant data point in the Pinealon literature. It is still cells in a dish, not a person.

What do animal studies of Pinealon show?

In 5xFAD transgenic mice, a model bred to develop amyloid pathology, EDR prevented loss of dendritic spines in hippocampal neurons ^[1]. The study tested EDR alongside a related peptide, KED, and the same paper produced the gene-promoter docking predictions ^[1].

That finding is worth taking seriously as a starting hypothesis. It also comes from a rodent model of one specific disease pathway, run by one lab, and mouse neuroprotection findings have a long history of failing to translate into human outcomes.

Has Pinealon been tested in humans?

No randomized controlled trial of Pinealon exists in any jurisdiction, and none is registered. The only human-level source is a 2013 narrative review describing clinical use of short peptide bioregulators, Pinealon among them, alongside related agents like Semax and Cortexin, in elderly patients ^[4].

That paper reviews clinical application, not a controlled study: it reports no randomization, no placebo arm, and no blinding ^[4]. It establishes that the compound has been administered to people in a clinical setting in Russia. It does not establish whether Pinealon produced an effect beyond what would have happened anyway.

The Pinealon evidence grade therefore sits at E, minimal. Five substantive sources exist, so the grade is not about an empty file. Nearly all of that work comes from one research group, almost none of it is randomized or controlled, and none of it is a human clinical trial of Pinealon. Mechanistically plausible is a fair description. Research-supported, in the sense that phrase usually implies independent replication and controlled human data, is not.

The Cortexin evidence and the Semax evidence cover two of the agents reviewed alongside it.

Where do Pinealon dosing protocols come from?

Pinealon dosing figures come from the supplement and peptide community, not from a study. The numbers repeated across forums and product pages, commonly 5-10mg/day, injected or intranasal, cycled for 10-20 days, trace to no pharmacokinetic study, dose-ranging trial, or clinical protocol.

No published study measured Pinealon absorption, half-life, or dose-response in humans. Those numbers appear to have started as a community estimate and propagated by repetition until they read as settled fact. That does not make them wrong by default. No one selling or discussing Pinealon can point to the study that produced them, because no such study exists.

The oral-versus-injectable question compounds the gap. Short peptides taken by mouth are generally degraded by digestive peptidases before meaningful amounts reach systemic circulation, and none of the cited studies measured oral bioavailability of EDR specifically. Claims about oral dosing effectiveness are unsupported. Why peptides can't be swallowed covers that degradation problem.

Is Pinealon the same as Epitalon?

Pinealon is not Epitalon: they are different peptides, EDR versus AEDG, proposed for different tissue targets and studied in largely separate papers.

Pinealon's proposed target is the central nervous system. Epitalon's is pineal and telomerase-related aging. The two are frequently stacked and discussed interchangeably online, and both evidence bases are separate and equally unresolved. Treating them as one compound with two names obscures that neither one's evidence transfers to the other. The Epitalon evidence covers that compound on its own terms.

What is still unknown about Pinealon?

Everything a person would need before using Pinealon remains untested:

• Human pharmacokinetics. No study measures absorption, half-life, or dose-response in people.
• Dose. No effective or safe human dose has been established.
• Long-term safety. No study follows repeated cycles in humans.
• Human effect. Whether the neuroprotective and antioxidant effects seen in rodent brains or cultured human-derived neurons produce any measurable outcome in a living person has never been tested.

The 2024 induced-neuron study is a meaningful step toward human relevance, because it used human donor cells. It stopped at a borderline-significant trend in one oxidative damage marker ^[5], short of a demonstrated clinical benefit. Anyone using Pinealon today is extending a hypothesis built on rodent models and one lab's cell cultures directly onto themselves, skipping the controlled human testing that would make the leap evidence-based rather than exploratory.